Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

Exact Sciences Corp. (NASDAQ: EXAS), a leading provider of cancer screening and diagnostic tests, will present three ...

Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences Corp. (Nasdaq: EXAS), a leading provider of cancer screening and diagnostic tests, today announced that the ...

Columbia Acorn Fund, distributed by Columbia Management Investment Distributors, released its third-quarter 2024 investor ...

Exact Sciences Corp ( (EXAS) ) has released its Q3 earnings. Here is a breakdown of the information Exact Sciences Corp presented to its ...

Shares of Exact Sciences tumbled after the company cut its full-year outlook and posted third-quarter results that missed estimates. The stock fell 29%, to $50.51, in after-hours trading Tuesday.

Exact Sciences' Q3 report led to a ~25% drop in share price, due to a slight guidance cut and narrow revenue miss. Learn more ...

The biomedical giant best known for its Cologuard at-home colon cancer screening test reported a loss of $38.2 million, or $0.21 per share, on revenue of $708.7 million.

(2) Represents stock-based compensation expense and 401(k) match expense. The Company matches a portion of Exact Sciences employees’ contributions annually in the form of the Company’s common ...

The Company matches a portion of Exact Sciences employees’ contributions ... s Oncotype DX Genomic Prostate Score® (“GPS”) test to MDxHealth SA (“MDxHealth”) in August 2022 and the ...